Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis

10/15/2021 | 07:04am EST

By Michael Dabaie

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of risankizumab alone or in combination with methotrexate for the treatment of active psoriatic arthritis.

The recommendation covers adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs. The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the EU.

The CHMP positive opinion was supported by data from two pivotal Phase 3 studies.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

10-15-21 0904ET

All news about ABBVIE INC.
11/24Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating
MT
11/24NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/23AbbVie Shares Rise After Societe Generale's Upgrade, Price Target Hike
MT
11/23Societe Generale Upgrades AbbVie to Buy from Hold, Raises Price Target to $172 From $11..
MT
11/23WALL STREET STOCK EXCHANGE : The Fed cannot stop Covid
11/23AbbVie to Present at the Evercore ISI Conference
PR
11/23AbbVie to Present at the Piper Sandler Healthcare Conference
PR
11/23ANALYST RECOMMENDATIONS : AbbVie, AIG, CBRE, Stoneco, Vonage...
11/18AbbVie Expands Immunology Portfolio in the European Union with the European Commission ..
AQ
11/18AbbVie Announces First Provincial Reimbursement for VENCLEXTA« (venetoclax) with Obinut..
AQ
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 248 M - -
Net income 2021 13 672 M - -
Net Debt 2021 63 490 M - -
P/E ratio 2021 15,6x
Yield 2021 4,45%
Capitalization 207 B 207 B -
EV / Sales 2021 4,80x
EV / Sales 2022 4,30x
Nbr of Employees 50 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 116,89 $
Average target price 130,14 $
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.9.09%206 648
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027